KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash & Equivalents: 2014-2024

Historic Cash & Equivalents for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Dec 2024 value amounting to $83.4 million.

  • Aurinia Pharmaceuticals' Cash & Equivalents rose 97.05% to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 97.05%. This contributed to the annual value of $83.4 million for FY2024, which is 70.71% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Cash & Equivalents stood at $83.4 million for FY2024, which was up 70.71% from $48.9 million recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year Cash & Equivalents high stood at $272.4 million for FY2020, and its period low was $48.9 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $75.5 million, with a median of $83.4 million in 2024.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Cash & Equivalents slumped by 59.39% in 2022 and then soared by 70.71% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Cash & Equivalents (Yearly) stood at $272.4 million in 2020, then fell by 14.85% to $231.9 million in 2021, then slumped by 59.39% to $94.2 million in 2022, then crashed by 48.10% to $48.9 million in 2023, then spiked by 70.71% to $83.4 million in 2024.